FDA clears pioglitazone for type-2 diabetes

被引：0

|

作者：

不详

机构：

来源：

DRUG NEWS & PERSPECTIVES | 1999年 / 12卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：370 / 370

页数：1

相关论文

共 50 条

[21] Long-term efficacy of oral insulin and pioglitazone combination therapy for treatment of type-2 diabetes
Lewin, A
Modi, P
DIABETES, 2001, 50 : A69 - A69
[22] Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes
Sudarshan K. Vijay
Manish Mishra
Hemant Kumar
K. Tripathi
Acta Diabetologica, 2009, 46 : 27 - 33
[23] THE GENETICS OF TYPE-2 DIABETES
KNOWLER, WC
DIABETES 1988, 1989, 800 : 489 - 492
[24] WINE AND TYPE-2 DIABETES
GIN, H
DIABETIC MEDICINE, 1994, 11 (08) : 811 - 811
[25] Pioglitazone in the Treatment of Diabetes Mellitus Type 2
Zach, Herwig
JOURNAL FUR HYPERTONIE, 2011, 15 (04): : 58 - 58
[26] FDA clears Tamiflu
不详
NEW SCIENTIST, 2005, 188 (2527) : 5 - 5
[27] FDA CLEARS ASPARTAME
不详
FOOD ENGINEERING, 1981, 53 (08): : 154 - 155
[28] A RANDOMISED CONTROL TRIAL OF COMPARITIVE EFFICACY OF METFORMIN, PIOGLITAZONE & ROSUVASTATIN IN PATIENTS WITH METABOLIC SYNDROME WITH TYPE-2 DIABETES
Mukherjee, I.
DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A241 - A242
[29] COMPARATIVE EFFECTS OF ROSIGLITAZONE AND PIOGLITAZONE ON FASTING AND POSTPRANDIAL LDL-SIZE AND SUBCLASSES IN PATIENTS WITH TYPE-2 DIABETES
Berneis, K.
Rizzo, M.
Stettler, C.
Chappuis, B.
Diem, P.
Christ, E.
ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 72 - 72
[30] Evaluation of the effects of pioglitazone on perivascular adipose tissue function, properties, and structure in a rat model of type-2 diabetes
Civelek, Erkan
Karaman, Ecem Fatma
Ozden, Sibel
Buyukpinarbasili, Nur
Dogan, B. Sonmez Uyde
Durman, Deniz Kaleli
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2025, 103 (01) : 12 - 28

← 1 2 3 4 5 →